UBS AM
EVFM

UBS AM’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

UBS AM’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,007
Closed -$145K – 2554
2017
Q1 		$145K Sell
1,007
-39
-4% -$5.06K ﹤0.01% 2253
2016
Q4 		$105K Hold
1,046
– – ﹤0.01% 2243
2016
Q3 		$105K Sell
1,046
-494
-32% -$45.3K ﹤0.01% 2572
2016
Q2 		$135K Sell
1,540
-39
-2% -$3.49K ﹤0.01% 2548
2016
Q1 		$87K Buy
1,579
+53
+3% +$4.1K ﹤0.01% 2582
2015
Q4 		$191K Sell
1,526
-1,348
-47% -$889K ﹤0.01% 2548
2015
Q3 		$2.09M Buy
+2,874
New +$3.09M ﹤0.01% 1410

Other funds holding EVFM

VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM's EVFM Position: Q2 2017 in Review

UBS AM sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2017, closing a stake of 1,007 shares — an estimated $145K sold.

UBS AM first reported a position in EVFM in Q3 2015 and held it in 7 quarters. The position peaked at $2.09M in Q3 2015. 15 funds tracked by Wall St. Rank hold EVFM as of Q2 2017.

  • UBS AM reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • UBS AM sold 1,007 Evofem Biosciences, Inc. Common Stock shares in Q2 2017, an estimated $145K.
  • UBS AM first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2015 and held it in 7 quarters.
  • UBS AM's Evofem Biosciences, Inc. Common Stock position peaked at $2.09M in Q3 2015.
  • 15 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2017.

Based on UBS AM's 13F filing for Q2 2017, filed 11 Aug 2017.